دورية أكاديمية
أعرض في EDS

Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trial.

التفاصيل البيبلوغرافية
العنوان: Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trial.
المؤلفون: Crowell TA; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland., Ritz J; Harvard T.H. Chan School of Public Health, Boston, Massachusetts., Zheng L; Harvard T.H. Chan School of Public Health, Boston, Massachusetts., Naqvi A; University of Pittsburgh, Pittsburgh, Pennsylvania., Cyktor JC; University of Pittsburgh, Pittsburgh, Pennsylvania., Puleo J; Harvard T.H. Chan School of Public Health, Boston, Massachusetts., Clagett B; Case Western Reserve University, Cleveland, Ohio, USA., Lama JR; Asociación Civil Impacta Salud y Educación, Lima, Peru., Kanyama C; University of North Carolina Project, Lilongwe, Malawi., Little SJ; University of California San Diego, San Diego, California., Cohn SE; Northwestern University Feinberg School of Medicine, Chicago, Illinois., Riddler SA; University of Pittsburgh, Pittsburgh, Pennsylvania., Collier AC; University of Washington, Seattle, Washington., Heath SL; University of Alabama @ Birmingham, Birmingham, Alabama, USA., Tantivitayakul P; SEARCH Foundation, Bangkok, Thailand., Grinsztejn B; Institute de Pesquisa Clinica Evandro Chagas, Rio de Janeiro, Brazil., Arduino RC; McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, Texas., Rooney JF; Gilead Sciences, Foster City, California, USA., van Zyl GU; Stellenbosch University, Cape Town, South Africa., Coombs RW; University of Washington, Seattle, Washington., Fox L; Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA., Ananworanich J; Amsterdam UMC, Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands., Eron JJ; University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Sieg SF; Case Western Reserve University, Cleveland, Ohio, USA., Mellors JW; University of Pittsburgh, Pittsburgh, Pennsylvania., Daar ES; Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California, USA.
مؤلفون مشاركون: AIDS Clinical Trials Group (ACTG) A5354/EARLIER Study Team
المصدر: AIDS (London, England) [AIDS] 2024 Jul 01; Vol. 38 (8), pp. 1141-1152. Date of Electronic Publication: 2024 Mar 13.
نوع المنشور: Journal Article; Multicenter Study; Clinical Trial; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 8710219 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-5571 (Electronic) Linking ISSN: 02699370 NLM ISO Abbreviation: AIDS Subsets: MEDLINE
أسماء مطبوعة: Publication: 1998- : London, England : Lippincott Williams & Wilkins
Original Publication: London : Gower Academic Journals, c1987-
مواضيع طبية MeSH: HIV Infections*/drug therapy , HIV Infections*/immunology, Humans ; Female ; Adult ; Male ; Young Adult ; Anti-Retroviral Agents/therapeutic use ; Viral Load ; CD4-Positive T-Lymphocytes/immunology ; DNA, Viral/analysis ; DNA, Viral/blood ; Treatment Outcome ; Asia ; Africa
مستخلص: Objective: To assess how antiretroviral therapy (ART) initiation during acute or early HIV infection (AEHI) affects the viral reservoir and host immune responses.
Design: Single-arm trial of ART initiation during AEHI at 30 sites in the Americas, Africa, and Asia.
Methods: HIV DNA was measured at week 48 of ART in 5 million CD4 + T cells by sensitive qPCR assays targeting HIV gag and pol . Peripheral blood mononuclear cells were stimulated with potential HIV T cell epitope peptide pools consisting of env , gag , nef, and pol peptides and stained for expression of CD3, CD4, CD8, and intracellular cytokines/chemokines.
Results: From 2017 to 2019, 188 participants initiated ART during Fiebig stages I ( n  = 6), II ( n  = 43), III ( n  = 56), IV ( n  = 23), and V ( n  = 60). Median age was 27 years (interquartile range 23-38), 27 (14%) participants were female, and 180 (97%) cisgender. Among 154 virally suppressed participants at week 48, 100% had detectable HIV gag or pol DNA. Participants treated during Fiebig I had the lowest HIV DNA levels ( P  < 0.001). Week 48 HIV DNA mostly did not correlate with concurrent CD4 + or CD8 + T cell HIV-specific immune responses (rho range -0.11 to +0.19, all P  > 0.025). At week 48, the magnitude, but not polyfunctionality, of HIV-specific T cell responses was moderately reduced among participants who initiated ART earliest.
Conclusion: Earlier ART initiation during AEHI reduced but did not eliminate the persistence of HIV-infected cells in blood. These findings explain the rapid viral rebound observed after ART cessation in early-treated individuals with undetectable HIV DNA by less sensitive methods.
(Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
التعليقات: Comment in: AIDS. 2024 Jul 1;38(8):1263-1264. doi: 10.1097/QAD.0000000000003898. (PMID: 38814713)
References: Clin Infect Dis. 2018 May 2;66(10):1540-1549. (PMID: 29228130)
N Engl J Med. 2013 Nov 7;369(19):1828-35. (PMID: 24152233)
PLoS Genet. 2015 Feb 02;11(2):e1004914. (PMID: 25642847)
J Clin Microbiol. 2016 Apr;54(4):902-11. (PMID: 26763968)
J Infect Dis. 2022 Jun 15;225(12):2167-2175. (PMID: 35275599)
Blood. 2000 Mar 1;95(5):1743-51. (PMID: 10688833)
AIDS. 2011 Nov 13;25(17):2069-78. (PMID: 21860347)
J Exp Med. 2001 Jan 15;193(2):169-80. (PMID: 11148221)
J Infect Dis. 2006 Sep 15;194(6):734-9. (PMID: 16941338)
J Virus Erad. 2020 Jul 18;6(3):100004. (PMID: 33251022)
Retrovirology. 2013 May 29;10:56. (PMID: 23718762)
PLoS Pathog. 2012 Feb;8(2):e1002506. (PMID: 22319447)
Proc Natl Acad Sci U S A. 2015 Mar 10;112(10):E1126-34. (PMID: 25713386)
JAMA. 2018 Mar 20;319(11):1103-1112. (PMID: 29509839)
Nat Commun. 2019 Jan 24;10(1):412. (PMID: 30679439)
N Engl J Med. 1998 Mar 26;338(13):853-60. (PMID: 9516219)
AIDS. 2016 Jul 31;30(12):1943-50. (PMID: 27163706)
Clin Infect Dis. 2015 Jun 1;60(11):1715-21. (PMID: 25737374)
PLoS One. 2018 Oct 31;13(10):e0198924. (PMID: 30379808)
PLoS Med. 2016 May 10;13(5):e1002015. (PMID: 27163694)
AIDS. 2003 Sep 5;17(13):1871-9. (PMID: 12960819)
J Virol. 2014 Sep 1;88(17):10056-65. (PMID: 24965451)
Sci Transl Med. 2017 Dec 6;9(419):. (PMID: 29212716)
Lancet HIV. 2018 Jan;5(1):e35-e44. (PMID: 28978417)
AIDS. 2013 Nov 13;27(17):2775-86. (PMID: 24113395)
Int J STD AIDS. 2011 Mar;22(3):146-50. (PMID: 21464451)
Science. 1997 Nov 14;278(5341):1295-300. (PMID: 9360927)
N Engl J Med. 2016 Sep 22;375(12):1195. (PMID: 27653577)
AIDS. 2015 May 15;29(8):911-9. (PMID: 25730509)
Clin Infect Dis. 2021 Aug 2;73(3):e643-e651. (PMID: 33382405)
Sci Transl Med. 2017 Feb 15;9(377):. (PMID: 28202771)
Lancet HIV. 2016 Jan;3(1):e49-54. (PMID: 26762993)
PLoS Pathog. 2013 Mar;9(3):e1003211. (PMID: 23516360)
EBioMedicine. 2016 Sep;11:68-72. (PMID: 27460436)
Clin Infect Dis. 2017 Jan 15;64(2):124-131. (PMID: 27737952)
Lancet HIV. 2019 May;6(5):e297-e306. (PMID: 31000477)
Nat Med. 2018 Jul;24(7):923-926. (PMID: 29892063)
PLoS Pathog. 2017 Sep 20;13(9):e1006629. (PMID: 28931091)
Clin Infect Dis. 2022 Mar 9;74(5):865-870. (PMID: 34117753)
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3382-7. (PMID: 10737796)
Nat Med. 2020 Apr;26(4):498-501. (PMID: 32235883)
AIDS. 2024 Mar 15;38(4):607-610. (PMID: 38416554)
معلومات مُعتمدة: U01 AI069438 United States AI NIAID NIH HHS; UM1 AI069432 United States AI NIAID NIH HHS; UM1 AI069438 United States AI NIAID NIH HHS; UM1 AI069471 United States AI NIAID NIH HHS; UM1 AI069534 United States AI NIAID NIH HHS; UM1 AI069439 United States AI NIAID NIH HHS; UM1 AI069481 United States AI NIAID NIH HHS; UM1 AI068618 United States AI NIAID NIH HHS; UM1 AI069399 United States AI NIAID NIH HHS; UM1 AI069452 United States AI NIAID NIH HHS; UM1 AI069465 United States AI NIAID NIH HHS; UM1 AI069419 United States AI NIAID NIH HHS; UM1 AI069436 United States AI NIAID NIH HHS; UL1 TR000457 United States TR NCATS NIH HHS; UM1 AI068636 United States AI NIAID NIH HHS; UM1 AI069494 United States AI NIAID NIH HHS; UM1 AI069423 United States AI NIAID NIH HHS; UM1 AI069501 United States AI NIAID NIH HHS; P30 AI050409 United States AI NIAID NIH HHS; UM1 AI069476 United States AI NIAID NIH HHS; UM1 AI069424 United States AI NIAID NIH HHS; UL1 TR000124 United States TR NCATS NIH HHS; UL1 TR002489 United States TR NCATS NIH HHS; UM1 AI069412 United States AI NIAID NIH HHS; UM1 AI068634 United States AI NIAID NIH HHS; P30 AI027757 United States AI NIAID NIH HHS; UM1 AI106701 United States AI NIAID NIH HHS
المشرفين على المادة: 0 (Anti-Retroviral Agents)
0 (DNA, Viral)
تواريخ الأحداث: Date Created: 20240315 Date Completed: 20240530 Latest Revision: 20240816
رمز التحديث: 20240816
مُعرف محوري في PubMed: PMC11323228
DOI: 10.1097/QAD.0000000000003881
PMID: 38489580
قاعدة البيانات: MEDLINE
الوصف
تدمد:1473-5571
DOI:10.1097/QAD.0000000000003881